Test a reduced transplant plan for older leukemia patients
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial studies a “reduced-intensity” transplant plan for people age 55–65 who have certain blood cancers and a suitable donor. It may help older patients get the benefits of a transplant with less treatment burden, but it excludes people with serious organ problems or active infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between ages 55 and 65
- Have a suitable stem-cell donor: a matched sibling, a well-matched unrelated donor (9–10/10), or a half-matched (haplo-identical) donor
- Have one of these diagnoses: AML in remission, or MDS (any stage), or CMML (any stage)
- Be able to give informed consent
- Have liver, kidney, and heart test results that meet study limits
- Not have an active infection at the time of screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This study tests a way to lower the chance of graft-versus-host disease (a common side effect of stem cell transplants) by removing certain immune cells from the donor's stem cells before they are given to you. It is for older patients with acute leukemia or MDS who are getting a transplant.
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
Hear when a new Disease-free Survival trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.